UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 87.

Mostmans, Y; Cutolo, M; Giddelo, C; Decuman, S; Melsens, K; Declercq, H; Vandecasteele, E; De Keyser, F; Distler, O; Gutermuth, J; Smith, V (2017). The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review: SSc vasculopathy: The role of endothelial cells. Autoimmunity Reviews:Epub ahead of print.

Hoeper, M M; Apitz, C; Grünig, E; Halank, M; Ewert, R; Kaemmerer, H; Kabitz, H-J; Kähler, C; Klose, H; Leuchte, H; Ulrich, S; Olsson, K M; Distler, O; Rosenkranz, S; Ghofrani, H A (2016). Gezielte Therapie der pulmonal arteriellen Hypertonie: Empfehlungen der Kölner Konsensuskonferenz 2016. Deutsche Medizinische Wochenschrift, 141(S 01):S33-S41.

Wirz, E G; Jaeger, V K; Allanore, Y; Riemekasten, G; Hachulla, E; Distler, O; Airò, P; Carreira, P E; Tikly, M; Vettori, S; Balbir Gurman, A; Damjanov, N; Müller-Ladner, U; Distler, J; Li, M; Häusermann, P; Walker, U A (2016). Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Annals of the Rheumatic Diseases, 75(7):1285-1292.

Huang, J; Beyer, C; Palumbo-Zerr, K; Zhang, Y; Ramming, A; Distler, A; Gelse, K; Distler, O; Schett, G; Wollin, L; Distler, J H W (2016). Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Annals of the Rheumatic Diseases, 75(5):883-890.

Wohlfahrt, T; Usherenko, S; Englbrecht, M; Dees, C; Weber, S; Beyer, C; Gelse, K; Distler, O; Schett, G; Distler, J H W; Ramming, A (2016). Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis. Annals of the Rheumatic Diseases, 75(3):623-626.

Mattsson, M; Boström, C; Mihai, C; Stöcker, J; Geyh, S; Stummvoll, G; Gard, G; Möller, B; Hesselstrand, R; Sandqvist, G; Draghicescu, O; Gherghe, A M; Voicu, M; Distler, O; Smolen, J S; Stamm, T (2015). Personal factors in systemic sclerosis and their coverage by patient-reported outcome measures: A multicentre European qualitative study and literature review. European Journal of Physical and Rehabilitation Medicine, 51(4):405-421.

Rauch, P J; Müllhaupt, B; Biedermann, L; Manz, M G; Ruschitzka, F; Flammer, A; Segerer, S T; Mohebbi, N; Jung, H H; Moch, H; Ikenberg, K; Aguzzi, A; Nuvolone, M; Distler, O; Rauch, A; Fehr, T H; Gerber, B (2014). Systemische Amyloidosen. Swiss Medical Forum, 14(50):943-948.

Distler, O (2013). Frühkollagenosen. Zeitschrift für Rheumatologie, 72(10):947.

Beyer, C; Distler, O; Distler, J H W (2012). Biomarkers of fibrosis. In: Varga, J; Denton, C P; Wigley, F M. Scleroderma: From Pathogenesis to Comprehensive Management. Boston: Springer, 283-290.

Foocharoen, C; Distler, O; Becker, M; Müller-Ladner, U; von Mühlen, C; Leuchten, N; Walker, U A (2012). Clinical correlations of hypocomplementaemia in systemic sclerosis: an analysis of the EULAR Scleroderma Trial and Research group (EUSTAR) database. Scandinavian Journal of Rheumatology, 41(3):243-246.

Avouac, J; Palumbo, K; Tomcik, M; Zerr, P; Dees, C; Horn, A; Maurer, B; Akhmetshina, A; Beyer, C; Sadowski, A; Schneider, H; Shiozawa, S; Distler, O; Schett, G; Allanore, Y; Distler, J H W (2012). Inhibition of AP-1 signaling abrogates TGF-ß mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis and Rheumatism, 64(5):1642-1652.

Fransen, J; Johnson, S R; van den Hoogen, F; Baron, M; Allanore, Y; Carreira, P E; Czirják, L; Denton, C P; Distler, O; Furst, D E; Gabrielli, A; Herrick, A; Inanc, M; Kahaleh, B; Kowal-Bielecka, O; Medsger, T A; Mueller-Ladner, U; Riemekasten, G; Sierakowski, S; Valentini, G; Veale, D; Vonk, M C; Walker, U; Chung, L; Clements, P J; Collier, D H; Csuka, M E; Jimenez, S; Merkel, P A; Seibold, J R; Silver, R; Steen, V; Tyndall, A; Matucci-Cerinic, M; Pope, J E; Khanna, D (2012). Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise with the ACR/EULAR working committee for classification criteria in systemic sclerosis. Arthritis Care and Research, 64(3):351-357.

Schmeiser, T; Saar, P; Jin, D; Noethe, M; Müller, A; Soydan, N; Hardt, P D; Jaeger, C; Distler, O; Roeb, E; Bretzel, R G; Müller-Ladner, U (2012). Profile of gastrointestinal involvement in patients with systemic sclerosis. Rheumatology International, 32(8):2471-2478.

Winklehner, A; Berger, N; Maurer, B; Distler, O; Alkadhi, H; Frauenfelder, T (2012). Screening for interstitial lung disease in systemic sclerosis: the diagnostic accuracy of HRCT image series with high increment and reduced number of slices. Annals of the Rheumatic Diseases, 71(4):549-552.

Stamm, T A; Mattsson, M; Mihai, C; Stöcker, J; Binder, A; Bauernfeind, B; Stummvoll, G; Gard, G; Hesselstrand, R; Sandqvist, G; Draghicescu, O; Gherghe, A M; Voicu, M; Machold, K P; Distler, O; Smolen, J S; Boström, C (2011). Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries. Annals of the Rheumatic Diseases, 70(6):1074-1079.

Distler, J H W; Strapatsas, T; Huscher, D; Dees, C; Akhmetshina, A; Kiener, H P; Tarner, I H; Maurer, B; Walder, M; Michel, B; Gay, S; Smolen, J S; Müller-Ladner, U; Schett, G; Distler, O (2011). Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. Annals of the Rheumatic Diseases, 70(7):1197-1202.

Beyer, C; Distler, J H W; Allanore, Y; Aringer, M; Avouac, J; Czirják, L; Cutolo, M; Damjanov, N; Del Galdo, F; Fligelstone, K; Guiducci, S; Kowal-Bielecka, O; van Laar, J M; Martucci-Cerinic, M; Müller-Ladner, U; Riemekasten, G; Tarner, I H; Tyndall, A; Kennedy, A T; Valentini, G; Vettori, S; Walker, U A; Denton, C; Distler, O (2011). EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. Annals of the Rheumatic Diseases, 70(7):1178-1182.

Lang, V; Distler, O; Distler, J H W (2011). Early and late pathological events in scleroderma. Kilchberg, Schweiz: European League Against Rheumatism EULAR.

Distler, O (2011). Endokrinologie und Rheumatologie. Zeitschrift für Rheumatologie, 70(9):739.

Jüngel, A; Distler, J H W; Gay, S; Distler, O (2011). Epigenetic modifications: novel therapeutic strategies for systemic sclerosis? Expert Review of Clinical Immunology, 7(4):475-480.

Moosig, F; Distler, O (2011). Genetik in der Rheumatologie. Zeitschrift für Rheumatologie, 70(3):185.

Iwamoto, N; Distler, O (2011). In depths discussion: Potential vascular and fibrotic targets for drug intervention. Kilchberg, Schweiz: European League Against Rheumatism EULAR.

Avouac, J; Fürnrohr, B G; Tomcik, M; Palumbo, K; Zerr, P; Horn, A; Dees, C; Akhmetshina, A; Beyer, C; Distler, O; Schett, G; Allanore, Y; Distler, J H W (2011). Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis and Rheumatism, 63(3):800-809.

Distler, J H W; Akhmetshina, A; Dees, C; Jüngel, A; Stürzl, M; Gay, S; Pisetsky, D S; Schett, G; Distler, O (2011). Induction of apoptosis in circulating angiogenic cells by microparticles. Arthritis and Rheumatism, 63(7):2067-2077.

Dees, C; Zerr, P; Tomcik, M; Beyer, C; Horn, A; Akhmetshina, A; Palumbo, K; Reich, N; Zwerina, J; Sticherling, M; Mattson, M P; Distler, O; Schett, G; Distler, J H W (2011). Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis and Rheumatism, 63(5):1396-1404.

Bergmann, C; Akhmetshina, A; Dees, C; Palumbo, K; Zerr, P; Beyer, C; Zwerina, J; Distler, O; Schett, G; Distler, J H W (2011). Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway. Annals of the Rheumatic Diseases, 70(12):2191-2198.

Distler, J H W; Jordan, S; Airo, P; Alegre-Sancho, J J; Allanore, Y; Balbir Gurman, A; Caporali, R; Caramaschi, P; Carreira, P E; Chizzolini, C; Cutolo, M; Tuncay Duruöz, M; Farge-Bancel, D; Hesselstrand, R; Iannone, F; De Keyser, F; Kucharz, E J; Launay, D; García de la Peña Lefebvre, P; Lukacova, O; Marasini, B; Martinovic, D; Marques Neto, J F; Radic, M; Rednic, S; Riemekasten, G; Rovensky, J; Seidel, M F; Senel, S; Smith, V; Sunderkötter, C; Ton, E; van Laar, J M; Matucci-Cerinic, M; Müller Ladner, U; Distler, O (2011). Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clinical and Experimental Rheumatology, 29(2 Suppl 65):S40-S45.

Guiducci, S; Ricci, L; Romano, E; Ceccarelli, C; Distler, J H W; Miniati, I; Calabri, G B; Distler, O; Matucci Cerinic, M; Falcini, F (2011). Microparticles and Kawasaki disease: a marker of vascular damage? Clinical and Experimental Rheumatology, 29(1 Suppl 64):S121-S125.

Reich, N; Beyer, C; Gelse, K; Akhmetshina, A; Dees, C; Zwerina, J; Schett, G; Distler, O; Distler, J H W (2011). Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts. Journal of Cellular and Molecular Medicine, 15(4):756-762.

Dees, C; Tomcik, M; Zerr, P; Akhmetshina, A; Horn, A; Palumbo, K; Beyer, C; Zwerina, J; Distler, O; Schett, G; Distler, J H W (2011). Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Annals of the Rheumatic Diseases, 70(7):1304-1310.

Dees, C; Akhmetshina, A; Zerr, P; Reich, N; Palumbo, K; Horn, A; Jüngel, A; Beyer, C; Krönke, G; Zwerina, J; Reiter, R; Alenina, N; Maroteaux, L; Gay, S; Schett, G; Distler, O; Distler, J H W (2011). Platelet-derived serotonin links vascular disease and tissue fibrosis. Journal of Experimental Medicine, 208(5):961-972.

Avouac, J; Fransen, J; Walker, U A; Riccieri, V; Smith, V; Muller, C; Miniati, I; Tarner, I H; Randone, S B; Cutolo, M; Allanore, Y; Distler, O; Valentini, G; Czirjak, L; Müller-Ladner, U; Furst, D E; Tyndall, A; Matucci-Cerinic, M (2011). Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Annals of the Rheumatic Diseases, 70(3):476-481.

Denton, C P; Avouac, J; Behrens, F; Furst, D E; Foeldvari, I; Humbert, M; Huscher, D; Kowal-Bielecka, O; Matucci-Cerinic, M; Nash, P; Opitz, C F; Pittrow, D; Rubin, L J; Seibold, J R; Distler, O (2011). Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Research & Therapy, 13(3):114.

Palumbo, K; Zerr, P; Tomcik, M; Vollath, S; Dees, C; Akhmetshina, A; Avouac, J; Yaniv, M; Distler, O; Schett, G; Distler, J H W (2011). The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 70(7):1320-1326.

Ghofrani, H A; Distler, O; Gerhardt, F; Gorenflo, M; Grünig, E; Haefeli, W E; Held, M; Hoeper, M M; Kähler, C M; Kaemmerer, H; Klose, H; Köllner, V; Kopp, B; Mebus, S; Meyer, A; Miera, O; Pittrow, D; Riemekasten, G; Rosenkranz, S; Schranz, D; Voswinckel, R; Olschewski, H (2011). Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011. International Journal of Cardiology, 154 (Suppl. 1):S20-S33.

Iwamoto, N; Distler, J H W; Distler, O (2011). Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. Current Rheumatology Reports, 13(1):21-7.

Avouac, J; Kowal-Bielecka, O; Pittrow, D; et al; Distler, O (2010). Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Annals of the Rheumatic Diseases, 69(7):1360-1363.

Beyer, C; Schett, G; Distler, O; Distler, J H W (2010). Animal models of systemic sclerosis: Prospects and limitations. Arthritis and Rheumatism, 62(10):2831-2844.

Beyer, C; Distler, J H W; Distler, O (2010). Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? Swiss Medical Weekly, 140:w13050.

Tyndall, A J; Bannert, B; Vonk, M; et al; Distler, O; Chizzolini, C (2010). Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Annals of the Rheumatic Diseases, 69(10):1809-1815.

Kowal-Bielecka, O; Avouac, J; Pittrow, D; Huscher, D; Behrens, F; Denton, C P; Foeldvari, I; Humbert, M; Matucci-Cerinic, M; Nash, P; Opitz, C F; Rubin, L J; Seibold, J R; Strand, V; Furst, D E; Distler, O (2010). Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. Journal of Rheumatology, 37(1):105-115.

Distler, O; Eich, W; Dokoupilova, E; Dvorak, Z; Fleck, M; Gaubitz, M; Hechler, M; Jansen, J P; Krause, A; Bendszus, M; Pache, L; Reiter, R; Müller-Ladner, U (2010). Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: Results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis and Rheumatism, 62(1):291-300.

Marquart, S; Zerr, P; Akhmetshina, A; Palumbo, K; Reich, N; Tomcik, M; Horn, A; Dees, C; Engel, M; Zwerina, J; Distler, O; Schett, G; Distler, J H W (2010). Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis and Rheumatism, 62(11):3467-3476.

Distler, J H W; Distler, O (2010). Inflammation: Microparticles and their roles in inflammatory arthritides. Nature Reviews. Rheumatology, 6(7):385-386.

Huscher, D; Pittrow, D; Distler, O; Denton, C P; Foeldvari, I; Humbert, M; Matucci-Cerinic, M; Kowal-Bielecka, O; Avouac, J; Behrens, F; Nash, P; Opitz, C F; Rubin, L J; Seibold, J R; Strand, V; Furst, D E; EPOSS-OMERACT Group (2010). Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Clinical and Experimental Rheumatology, 28(2 S 58):S47-52.

Maurer, B; Stanczyk, J; Jüngel, A; Akhmetshina, A; Trenkmann, M; Brock, M; Kowal-Bielecka, O; Gay, R E; Michel, B A; Distler, J H W; Gay, S; Distler, O (2010). MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis and Rheumatism, 62(6):1733-1743.

Tamborrini, G; Distler, O; Schmet, M; Michel, B A (2010). Mixed crystal-induced arthropathy--a rare finding. Clinical and Experimental Rheumatology, 28(5):801.

Allanore, Y; Meune, C; Vonk, M C; et al; Distler, O; Walker, U A (2010). Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Annals of the Rheumatic Diseases, 69(1):218-221.

Distler, O; Gay, S (2010). Sklerodermie. Der Internist, 51(1):30-38.

Khanna, D; Seibold, J R; Wells, A; Distler, O; Allanore, Y; Denton, C; Furst, D E (2010). Systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials, outcome measures, and future study design. Current Rheumatology Review, 6(2):138-144.

Reich, N; Maurer, B; Akhmetshina, A; Venalis, P; Dees, C; Zerr, P; Palumbo, K; Zwerina, J; Nevskaya, T; Gay, S; Distler, O; Schett, G; Distler, J H W (2010). The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis and Rheumatism, 62(1):280-290.

Ghofrani, H A; Distler, O; Gerhardt, F; Gorenflo, M; Grünig, E; Haefeli, W E; Held, M; Hoeper, M M; Kähler, C M; Kaemmerer, H; Klose, H; Köllner, V; Kopp, B; Mebus, S; Meyer, A; Miera, O; Pittrow, D; Riemekasten, G; Rosenkranz, S; Schranz, D; Voswinckel, R; Olschewski, H (2010). Therapie der pulmonal arteriellen Hypertonie (PAH). Empfehlungen der Kölner Konsensus-Konferenz 2010. Deutsche Medizinische Wochenschrift, 135(Supl 3):S87-S101.

Distler, J H W; Distler, O (2010). Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Annals of the Rheumatic Diseases, 69 Sup:i48-i51.

Kowal-Bielecka, O; Distler, O (2010). Use of methotrexate in patients with scleroderma and mixed connective tissue disease. Clinical and Experimental Rheumatology, 28(5 S 61):S160-S163.

Chung, L; Distler, O; Hummers, L; Krishnan, E; Steen, V (2010). Vascular disease in systemic sclerosis. International Journal of Rheumatology, 2010:714172.

Venalis, P; Maurer, B; Akhmetshina, A; Busch, N; Dees, C; Stürzl, M; Zwerina, J; Jüngel, A; Gay, S; Schett, G; Distler, O; Distler, J H W (2009). Lack of inhibititory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo. Journal of Cellular and Molecular Medicine, 13(10):4185-4191.

Guiducci, S; Distler, J H W; Milia, A F; Miniati, I; Rogai, V; Manetti, M; Falcini, F; Ibba-Manneschi, L; Gay, S; Distler, O; Matucci-Cerinic, M (2009). Stiff skin syndrome: evidence for an inflammation-independent fibrosis? Rheumatology, 48(7):849-852.

Hemmatazad, H; Maciejewska Rodrigues, H; Maurer, B; Brentano, F; Pileckyte, M; Distler, J H W; Gay, R E; Michel, B A; Gay, S; Huber, L C; Distler, O; Jüngel, A (2009). Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis and Rheumatism, 60(5):1519-1529.

Beyer, C; Schett, G; Gay, S; Distler, O; Distler, J H W (2009). Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Research & Therapy, 11(2):220.

Akhmetshina, A; Dees, C; Busch, N; Beer, J; Sarter, K; Zwerina, J; Zimmer, A; Distler, O; Schett, G; Distler, J H W (2009). The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis and Rheumatism, 60(4):1129-1136.

Dragun, D; Distler, J H W; Riemekasten, G; Distler, O (2009). Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology. Arthritis and Rheumatism, 60(4):907-911.

Distler, J H W; Allanore, Y; Avouac, J; Giacomelli, R; Guiducci, S; Moritz, F; Akhmetshina, A; Walker, U A; Gabrielli, A; Müller-Ladner, U; Tyndall, A; Matucci-Cerinic, M; Distler, O (2009). EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Annals of the Rheumatic Diseases, 68(2):163-168.

Distler, J H W; Akhmetshina, A; Schett, G; Distler, O (2009). Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology, 48(2):98-103.

Akhmetshina, A; Venalis, P; Dees, C; Busch, N; Zwerina, J; Schett, G; Distler, O; Distler, J H W (2009). Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis and Rheumatism, 60(1):219-224.

Distler, J H W; Beyer, C; Schett, G; Lüscher, T F; Gay, S; Distler, O (2009). Endothelial progenitor cells: Novel players in the pathogenesis of rheumatic diseases. Arthritis and Rheumatism, 60(11):3168-3179.

Kurowska-Stolarska, M; Distler, J H; Jüngel, A; Rudnicka, W; Neumann, E; Pap, T; Wenger, R H; Michel, B A; Müller-Ladner, U; Gay, R E; Maslinski, W; Gay, S; Distler, O (2009). Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast-dependent osteoclastogenesis. Arthritis and Rheumatism, 60(12):3663-3675.

Khanna, D; Distler, O; Avouac, J; Behrens, F; Clements, P J; Denton, C; Foeldvari, I; Giannini, E; Huscher, D; Kowal-Bielecka, O; Lovell, D; Matucci-Cerinic, M; Mayes, M; Merkel, P A; Nash, P; Opitz, C F; Pittrow, D; Rubin, L; Seibold, J R; Steen, V; Strand, C V; Tugwell, P S; Varga, J; Zink, A; Furst, D E (2009). Measures of response in clinical trials of systemic sclerosis: the combined response index for systemic sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). Journal of Rheumatology, 36(10):2356-2361.

Müller-Ladner, U; Distler, O; Ibba-Manneschi, L; Neumann, E; Gay, S (2009). Mechanisms of vascular damage in systemic sclerosis. Autoimmunity, 42(7):587-595.

Abraham, D J; Krieg, T; Distler, J; Distler, O (2009). Overview of pathogenesis of systemic sclerosis. Rheumatology, 48(Suppl ):iii3-iii7.

Maurer, B; Walder, M; Gay, R E; Gay, S; Distler, O (2009). Systemische Sklerose: Zielkriterien der Behandlung. Zeitschrift für Rheumatologie, 68(1):37-43.

Maurer, B; Busch, N; Jüngel, A; Pileckyte, M; Gay, R E; Michel, B A; Schett, G; Gay, S; Distler, J; Distler, O (2009). Transcription factor Fos-Related Antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation, 120(23):2367-2376.

Saur, N; Distler, O; Mueller, N J (2008). Bakterielle Arthritis? Gonokokken-Infektion trotz negativen Kulturen. Praxis, 97(18):977-983.

Distler, O; Behrens, F; Pittrow, D; Huscher, D; Denton, C P; Foeldvari, I; Humbert, M; Matucci-Cerinic, M; Nash, P; Opitz, C F; Rubin, L J; Seibold, J R; Furst, D E (2008). Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis and Rheumatism, 59(6):867-875.

Akhmetshina, A; Dees, C; Pileckyte, M; Maurer, B; Axmann, R; Jüngel, A; Zwerina, J; Gay, S; Schett, G; Distler, O; Distler, J H W (2008). Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB Journal, 22(7):2214-2222.

Distler, J; Distler, O (2008). Novel treatment approaches to fibrosis in scleroderma. Rheumatic Disease Clinics of North America, 34(1):145-159.

Distler, J H W; Schett, G; Gay, S; Distler, O (2008). The controversial role of tumor necrosis factor alpha in fibrotic diseases. Arthritis and Rheumatism, 58(8):2228-2235.

Guiducci, S; Distler, J H W; Jüngel, A; Huscher, D; Huber, L C; Michel, B A; Gay, R E; Pisetsky, D S; Gay, S; Matucci-Cerinic, M; Distler, O (2008). The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis and Rheumatism, 58(9):2845-2853.

Huber, L C; Distler, J H W; Moritz, F; Hemmatazad, H; Hauser, T; Michel, B A; Gay, R E; Matucci-Cerinic, M; Gay, S; Distler, O; Jüngel, A (2007). Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis and Rheumatism, 56(8):275-264.

Huber, L C; Jüngel, A; Distler, J H W; Moritz, F; Gay, R E; Michel, B A; Pisetsky, D S; Gay, S; Distler, O (2007). The role of membrane lipids in the induction of macrophage apoptosis by microparticles. Apoptosis, 12(2):363-374.

Distler, J H W; Jüngel, A; Huber, L C; Schulze-Horsel, U; Zwerina, J; Gay, R E; Michel, B A; Hauser, T; Schett, G; Gay, S; Distler, O (2007). Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis and Rheumatism, 56(1):311-322.

Abraham, D; Distler, O (2007). How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Research and Therapy, 9 (Sup:1-10.

Koch, A E; Distler, O (2007). Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Research and Therapy, 9 (Sup:1-9.

Huber, L C; Distler, O; Gay, R E; Gay, S (2006). Antisense strategies in degenerative joint diseases: sense or nonsense? Advanced Drug Delivery Reviews, 58(2):285-299.

Distler, J H W; Jüngel, A; Huber, L C; Seemayer, C A; Reich, C F; Gay, R E; Michel, B A; Fontana, A; Gay, S; Pisetsky, D S; Distler, O (2005). The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 102(8):2892-2897.

Distler, J H W; Wenger, R H; Gassmann, M; Kurowska, M; Hirth, A K; Gay, S; Distler, O (2004). Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. Arthritis and Rheumatism, 50(1):10-23.

Distler, O; Del Rosso, A; Giacomelli, R; Cipriani, P J; Conforti, M L; Guiducci, S G; Gay, R E; Michel, B A; Brühlmann, P; Müller-Ladner, U; Gay, S; Matucci-Cerinic, M (2002). Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Research, 4(6):R11-10.

Scheid, A; Wenger, R H; Schäffer, L; Camenisch, I; Distler, O; Ferenc, A; Cristina, H G; Ryan, H E; Johnson, R S; Wagner, K F; Stauffer, U G; Bauer, C; Gassmann, M; Meuli, M (2002). Physiologically low oxygen concentrations in fetal skin regulate hypoxia-inducible factor 1 and transforming growth factor-beta3. FASEB Journal, 16(3):411-413.

This list was generated on Sat Jul 22 23:54:58 2017 CEST.